Semnur’s SP102, addressing multi-billion dollar unmet market needs, in Pivotal Phase 3 Trial with Fast Track Status from the FDA With non-opioid ZTlido, RTX, and SP102 commercial and near-commercial product lines, Sorrento and its subsidiaries are addressing $63 billion market in pain managementRead More»
SP-102 Granted Fast Track Designation From The FDA Semnur Pharmaceuticals Announces The Launch Of The New Clinical Trial Website At www.clearbackpainstudy.com . Mountain View, Calif., Jan 7, 2018 /PRNewswire/ – Semnur Pharmaceuticals, Inc., a clinical stage specialty pharmaceutical companyRead More»
– Pharmacokinetic data supports previous preclinical results, demonstrating an extended product residency time at the site of epidural injection – Single epidural injection of SP-102 resulted in sustained analgesic effect, lasting over the entire observational period of one month – SP-102 is aRead More»
SAN DIEGO, Aug. 15, 2016 /PRNewswire/ — Scintilla Pharmaceuticals, Inc. (“Scintilla”), a subsidiary of Sorrento Therapeutics, Inc. (NASDAQ: SRNE; “Sorrento”), has entered into a binding term sheet to acquire Semnur Pharmaceuticals, Inc. (“Semnur”). Scintilla’s lead program is resiniferatoxinRead More»
Recognizing World’s Most Enterprising Technology Startups TiE50 is TiE Silicon Valley’s premier annual awards program keenly contested by thousands of technology start-ups worldwide. Awards are announced at TiEcon, the world’s largest conference for entrepreneurs.Read More»